Clinical Research Directory
Browse clinical research sites, groups, and studies.
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Sponsor: Novartis Pharmaceuticals
Summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients
Official title: A Post Marketing Surveillance of Jakavi® (Ruxolitinib) in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Key Details
Gender
All
Age Range
12 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
127
Start Date
2023-04-07
Completion Date
2026-05-09
Last Updated
2025-08-11
Healthy Volunteers
No
Conditions
Interventions
ruxolitinib
Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
Locations (11)
Novartis Investigative Site
Daegu, Dalseo gu, South Korea
Novartis Investigative Site
Wŏnju, Gangwon-do, South Korea
Novartis Investigative Site
Seoul, Seocho gu, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Jinju, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Taegu, South Korea